DYNAGEN INC
NT 10-K, 1998-04-01
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: SCHWAB CHARLES FAMILY OF FUNDS, 497, 1998-04-01
Next: SOUTH HERTFORDSHIRE UNITED KINGDOM FUND LTD, 10-K, 1998-04-01



<PAGE>   1
                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12b-25
                           Notification Of Late Filing
                                       of
                Form 10-K for Fiscal Year Ended December 31, 1997

                          COMMISSION FILE NO. 001-11352

            Nothing in this form shall be construed to imply that the
            Commission has verified any information contained herein.
           -----------------------------------------------------------

Part I.  REGISTRANT INFORMATION.

                                  DYNAGEN, INC.
                            (Full Name of Registrant)

                               840 MEMORIAL DRIVE
                     (Address of Principal Executive Office)

                               CAMBRIDGE, MA 02139
                           (City, State and Zip Code)

Part II. RULES 12B-25(B) AND (C).

         The registrant hereby seeks relief under Rule 12b-25(b) and in support
thereof states that:

                           (a)The reasons for the late filing of the subject
                  report that are described in Part III of this form could not
                  be eliminated without unreasonable effort or expense; and

                           (b)The subject Annual Report on Form 10-K will be
                  filed on or before the fifteenth calendar day following the
                  prescribed due date.

                  Part III.NARRATIVE.

                  DynaGen, Inc. (the "Company") is unable to meet its filing
                  deadline for the Form 10-K for the year ended December 31,
                  1997 without unreasonable effort or expense. The Company has
                  been informed by its independent auditors that additional time
                  is needed to complete the audit, the results of which will
                  affect the Company's Form 10-K and financial disclosure to be
                  included therein. Therefore, the Company is requesting an
                  extension on this Form 12b-25. The Company intends to file the
                  Form 10-K within the time period specified by Rule 12b-25 of
                  the Securities Exchange Act of 1934, as amended.


<PAGE>   2



Part IV. OTHER INFORMATION.

                  (1)Name and telephone number of person to contact in regard 
                     to this notification:

                     Dhananjay G. Wadekar  (617) 491-2527
                    (Name)                (Area Code)(Telephone Number)

                  (2)Have all other periodic reports required under
                     Section 13 or 15(d) of the Securities Exchange Act of 1934
                     during the preceding 12 months been filed?

                     (X)                                       ( ) No

                  (3)Is it anticipated that any significant change in results of
                     operations from the corresponding period for the last 
                     fiscal year will be reflected by the earnings statements to
                     be included in the subject report?

                     (X) Yes (see explanation below)           ( ) No

         If so, attach explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made:

         The Company had revenues of approximately $0.4 million for the
six-month transition period ended December 31, 1996, and had a net loss of
approximately $4.3 million. The Company's financial statements for 1997 will
reflect, for the first time, an entire year of consolidated operations of the
Company's subsidiary Able Laboratories, Inc. and approximately six months of
operations of the Company's subsidiary, Superior Pharmaceutical Company. These
acquisitions, and the Company's business activities during 1997, are expected to
cause a significant change in the Company's results of operations from the
twelve months ended December 31, 1996. Through the third quarter of 1997, the
Company had reported revenues of approximately $7.4 million, an operating loss
of approximately $7.1 million and a net loss of approximately $7.6 million.
Until the audit is completed and all necessary adjustments are made to the
Company's financial statements, revenue or net loss for the full year cannot be
expressed with certainty.

                                      * * *

         DynaGen, Inc. has caused this notification to be signed on its behalf 
by the undersigned thereunto duly authorized.


Dated: March 31, 1998                       By /S/ DHANANJAY G. WADEKAR
                                              -------------------------
                                                   Dhananjay G. Wadekar
                                                   Executive Vice President

<PAGE>   1

Wolf & Company, P.C.
One International Place
Boston, MA 02109

                                                              March 31, 1998

Securities and Exchange Commission
450 Fifth Street, N.S.
Washington, D.C.  20549

Gentlemen:

         This letter is written in response to the requirement of Rule 12b-25(c)
under the Securities and Exchange Act of 1934 and in satisfaction of item (c) of
Part II of Form 12b-25.

         We are the independent auditors of DynaGen, Inc. (the "Registrant").
The Registrant has stated in Part III of its filing on Form 12b-25 that it is
unable to timely file, without unreasonable effort or expense, its Annual Report
on Form 10-K for the year ended December 31, 1997 because our Firm has not yet
completed our audit of the financial statements of the Registrant for the year
ended December 31, 1997 and is therefore unable to furnish the required opinion
on such financial statements.

         We hereby advise you that we have read the statements made by the
Registrant in Part III of its filing on Form 12b-25 and agree with the
statements made therein. We are unable to complete our audit of the Registrant's
financial statements and furnish the required opinion for a timely filing as we
are still in the process of obtaining and analyzing evidential matter pertaining
to the Registrant's acquisition and financing activities and management's
business plans for the fiscal year ending December 31, 1998. Therefore, we have
not yet had sufficient time to complete the auditing procedure which we consider
necessary in these circumstances.

Very truly yours,



/s/ Wolf & Company, P.C.







© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission